Why AstraZeneca Shares Plunged 7.8% on Reports of a $400 Billion Bristol Myers Squibb Merger

AstraZeneca's stock fell as much as 7.8% intraday, settling around 6–7% lower . The sell-off made AstraZeneca the biggest decliner on the FTSE 100 index, which itself slipped only about 0.1% on the day . The Wall Street Journal reported that, had the losses held through the close, it would have marked the stock's largest single-day percentage drop since the day of the 2024 U.S. presidential election .

Key details of the reported talks

The talks were described as early and preliminary. No firm deal was confirmed, and neither company publicly acknowledged the negotiations. A source familiar with the matter told Reuters that AstraZeneca and BMS had discussed a possible combination, but details on structure were scarce . Some reports characterized the move as a potential takeover of BMS by AstraZeneca .

• Parties: AstraZeneca (UK-headquartered) and Bristol Myers Squibb (U.S.-headquartered)
• Reported structure: Potential takeover of BMS by AstraZeneca
• Combined value: Nearly $400 billion (~£300 billion)
• Projected ranking: Would become the world's fourth-largest drugmaker by market value
• Confirmation: Neither company confirmed; both declined to comment or said they do not comment on rumor or speculation

Market reactions: 'A clear message' of disapproval

AstraZeneca (AZN.L)

Shares fell 6–7% as investors "balked" at the deal logic, according to Reuters . Bloomberg characterized the price action as investors sending a "clear message" that they don't like the idea . Analysts at CNBC were described as "perplexed" . "A combination with Bristol does not make strategic or financial sense," Markus Manns, a portfolio manager, told Reuters . Russ Mould, investment director at AJ Bell, said the "initial market reaction to the reports is highly circumspect, reflecting understandable caution about the scale of the deal" .

Bristol Myers Squibb (BMY.N)

BMS shares rose slightly — about 0.69% at the market open — consistent with the deal being structured as an AstraZeneca acquisition of BMS, making BMS the acquired party that would receive a premium .

FTSE 100

The broader index was barely affected, slipping about 0.1%, as the AstraZeneca decline was largely offset by other sectors .

Why investors opposed the deal

1. Portfolio overlap

Both companies are heavily concentrated in oncology. A merger would combine two of the world's largest cancer-drug portfolios, raising concerns about limited diversification benefits and significant antitrust risk from overlapping pipelines and marketed products .

2. Size and integration risk

At nearly $400 billion, the integration would be enormous. Mergers on this scale have historically proven difficult to execute in the pharmaceutical industry, with cultural clashes and operational disruption being common pitfalls .

3. Questionable strategic rationale

Investors and analysts broadly questioned why Britain's biggest drugmaker, already a strong independent performer, would need a transformative acquisition of this size. As one analyst put it, the deal lacked clear strategic or financial sense .

Regulatory uncertainties

Because the talks were preliminary, no formal regulatory filings had been made. However, several major hurdles were immediately apparent:

• Antitrust risk: The combination of two oncology-heavy companies would almost certainly trigger deep reviews in the U.S. (FTC or DOJ), the UK (Competition and Markets Authority), and the European Union. Overlapping cancer drug pipelines and market shares would be a central issue.
• UK national interest: The UK government has a track record of intervening in takeovers of strategic domestic assets. In 2014, it helped block Pfizer's attempt to acquire AstraZeneca on national interest grounds . A similar dynamic, but in reverse — with AstraZeneca as the acquirer — could still raise political scrutiny.
• Cross-border complexity: The UK-U.S. structure would require approval from regulators in both countries, including potential review by the Committee on Foreign Investment in the United States (CFIUS), given the scale and healthcare sensitivity.

What happens next

As of August 3, 2026, the talks remained preliminary, with no formal deal announced or confirmed. Both companies were keeping their cards close to their chest. Whether the discussions proceed to a formal bid will depend on whether AstraZeneca's leadership can win over skeptical investors and navigate what would be one of the most complex M&A processes in pharmaceutical history.

For now, the market has delivered its verdict: a nearly $400 billion merger between two oncology-focused giants faces an uphill battle — and investors are not waiting around to see if it happens.